Hemogenyx Pharmaceuticals (LON:HEMO) Stock Price Up 4.6% – What’s Next?

Shares of Hemogenyx Pharmaceuticals Plc (LON:HEMO) traded up 4.6% during mid-day trading on Thursday . The company traded as high as GBX 664 and last traded at GBX 664. Approximately 4,433 shares were traded during trading, a decline of 81% from the average daily volume of 23,279 shares. The stock had previously closed at GBX 635.

Hemogenyx Pharmaceuticals Stock Performance

The company has a market capitalization of £45.15 million, a price-to-earnings ratio of -3.89 and a beta of 1.53. The firm has a fifty day simple moving average of GBX 739.39 and a 200 day simple moving average of GBX 830.23. The company has a debt-to-equity ratio of 167.66, a current ratio of 1.38 and a quick ratio of 6.72.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.